A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler L, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA

Open source

DOI: 10.1093/annonc/mdv264
Published: 2015 Sep
Container: Annals of oncology : official journal of the European Society for Medical Oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/annonc/mdv264,
  title = {A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.},
  author = {O'Neil BH and Scott AJ and Ma WW and Cohen SJ and Aisner DL and Menter AR and Tejani MA and Cho JK and Granfortuna J and Coveler L and Olowokure OO and Baranda JC and Cusnir M and Phillip P and Boles J and Nazemzadeh R and Rarick M and Cohen DJ and Radford J and Fehrenbacher L and Bajaj R and Bathini V and Fanta P and Berlin J and McRee AJ and Maguire R and Wilhelm F and Maniar M and Jimeno A and Gomes CL and Messersmith WA},
  year = {2015},
  journal = {Annals of oncology : official journal of the European Society for Medical Oncology},
  doi = {10.1093/annonc/mdv264},
  url = {https://doi.org/10.1093/annonc/mdv264}
}

RIS

TY  - JOUR
TI  - A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
AU  - O'Neil BH
AU  - Scott AJ
AU  - Ma WW
AU  - Cohen SJ
AU  - Aisner DL
AU  - Menter AR
AU  - Tejani MA
AU  - Cho JK
AU  - Granfortuna J
AU  - Coveler L
AU  - Olowokure OO
AU  - Baranda JC
AU  - Cusnir M
AU  - Phillip P
AU  - Boles J
AU  - Nazemzadeh R
AU  - Rarick M
AU  - Cohen DJ
AU  - Radford J
AU  - Fehrenbacher L
AU  - Bajaj R
AU  - Bathini V
AU  - Fanta P
AU  - Berlin J
AU  - McRee AJ
AU  - Maguire R
AU  - Wilhelm F
AU  - Maniar M
AU  - Jimeno A
AU  - Gomes CL
AU  - Messersmith WA
PY  - 2015
JO  - Annals of oncology : official journal of the European Society for Medical Oncology
DO  - 10.1093/annonc/mdv264
UR  - https://doi.org/10.1093/annonc/mdv264
ER  -

APA

BH, O., AJ, S., WW, M., SJ, C., DL, A., AR, M., MA, T., JK, C., J, G., L, C., OO, O., JC, B., M, C., P, P., J, B., R, N., M, R., DJ, C., J, R., L, F., R, B., V, B., P, F., J, B., AJ, M., R, M., F, W., M, M., A, J., CL, G., & WA, M. (2015). A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.. Annals of oncology : official journal of the European Society for Medical Oncology. https://doi.org/10.1093/annonc/mdv264

Source records

pubmed · retrieved 2026-09-26T17:31:59.105Z